The paraventricular thalamic nucleus and its projections in regulating reward and context associations.

https://doi.org/10.1523/ENEURO.0524-23.2024

Received: 11 December 2023
Revised: 23 January 2024
Accepted: 23 January 2024

Copyright © 2024 McDevitt et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

This Early Release article has been peer reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.
Title: The paraventricular thalamic nucleus and its projections in regulating reward and context associations.

Abbreviated Title: Reward Effects of Direct PVT Manipulation

Authors: Dillon S. McDevitt, Ph.D.\textsuperscript{1}, Quinn W. Wade, Ph.D.\textsuperscript{3}, Greer E. McKendrick, Ph.D.\textsuperscript{1}, Jacob Nelsen, B.S.\textsuperscript{2}, Mariya Starostina, B.S.\textsuperscript{2}, Nam Tran, B.S.\textsuperscript{2}, Julie A. Blendy, Ph.D.\textsuperscript{4}, & Nicholas M. Graziane, Ph.D.\textsuperscript{5}

\textsuperscript{1}Neuroscience Program, Penn State College of Medicine, Hershey, PA, 17033 USA

\textsuperscript{2}Doctor of Medicine Program, Penn State College of Medicine, Hershey, PA, 17033 USA

\textsuperscript{3}Department of Anesthesiology and Perioperative Medicine, Penn State College of Medicine, Hershey, PA, 17033 USA

\textsuperscript{4}Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

\textsuperscript{5}Departments of Anesthesiology and Perioperative Medicine and Pharmacology, Penn State College of Medicine, Hershey, PA, 17033 USA

* Correspondence: Nicholas Graziane, Ph.D.
Assistant Professor
Department of Anesthesiology and Perioperative Medicine and Pharmacology
The Pennsylvania State University
Milton S. Hershey Medical Center
Mail Code H187, Room C2846E
500 University Drive
Hershey, PA 17033
Phone: (717) 531-0003 x329159
Fax: (717) 531-0052
E-mail: ngraziane@pennstatehealth.psu.edu

Number of Pages: 53
Number of Figures: 11
Number of Tables: 5

Abstract: 271

Introduction: 576

Discussion: 2327

Conflict of Interest Statement: The authors have no financial or non-financial competing interests to declare

Acknowledgements: This project is supported by the National Institute on Drug Abuse (DA054374-JAB), Brain and Behavioral Research Foundation (NARSAD Young Investigator Award (27364NG)), the Pennsylvania Department of Health, and the Department of Anesthesiology and Perioperative Medicine at Penn State College of Medicine. We thank Drs. Karl Deisseroth and Bryan Roth for providing viral vectors.
ABSTRACT

The paraventricular thalamic nucleus (PVT) is a brain region that mediates aversive and reward-related behaviors as shown in animals exposed to fear conditioning, natural rewards, or drugs of abuse. However, it is unknown whether manipulations of the PVT, in the absence of external factors or stimuli (e.g., fear, natural rewards, or drugs of abuse) are sufficient to drive reward-related behaviors. Additionally, it is unknown whether drugs of abuse administered directly into the PVT are sufficient to drive reward-related behaviors. Here, using behavioral as well as pathway and cell-type specific approaches, we manipulate PVT activity as well as the PVT-to-nucleus accumbens shell (NAcSh) neurocircuit to explore reward phenotypes. First, whole-cell brain slice electrophysiology recordings on PVT neurons that project to the NAcSh showed that bath perfusion of morphine (10 μM) caused hyperpolarization of the resting membrane potential, increased rheobase, and decreased intrinsic membrane excitability. Additionally, we found that direct injections of morphine (50 ng) in the PVT of mice were sufficient to generate conditioned place preference (CPP) for the morphine-paired chamber. Mimicking the inhibitory effect of morphine, we employed a chemogenetic approach to inhibit PVT neurons that projected to the NAcSh and found that pairing the inhibition of these PVT neurons with a specific context evoked the acquisition of CPP. Lastly, using brain slice electrophysiology, we found that bath perfused morphine (10 μM) significantly reduced PVT excitatory synaptic transmission on both dopamine D1-receptor and D2-receptor expressing medium spiny neurons in the NAcSh, but that inhibiting PVT afferents in the NAcSh was not sufficient to evoke CPP. Together, these results provide valuable insights into the intricate interplay between the PVT and reward-related behaviors.
SIGNIFICANCE STATEMENT

This study investigates the direct impact of paraventricular thalamic nucleus (PVT) inhibition on reward-related behaviors, employing manipulations related to drugs of abuse, specifically morphine, as well as employing chemogenetic approaches that replicate the inhibitory effects induced by morphine. Our findings reveal that morphine exerts an inhibitory effect on PVT neurons projecting to the nucleus accumbens shell (NAcSh). Furthermore, local administration of morphine within the PVT elicits reward-related behaviors, a response mimicked by the inhibition of PVT neurons projecting to the NAcSh. These results firmly establish the PVT as an integral component of a complex neurocircuit involved in the acquisition of associations with opioid-related contexts. Additionally, these results provide compelling evidence linking the inhibition of PVT neurons to reward processes.
The paraventricular thalamic nucleus (PVT) regulates motivation, reward, aversion, and arousal via excitatory projections that extend throughout the reward network (Kelley et al., 2005; Browning et al., 2014; Matzeu et al., 2014; Kirouac, 2015; Millan et al., 2017; Zhou and Zhu, 2019; McGinty and Otis, 2020; Curtis et al., 2021; De Groote and de Kerchove d'Exaerde, 2021; Hartmann and Pleil, 2021; Iglesias and Flagel, 2021; Penzo and Gao, 2021). One particularly dense projection from the PVT is to the nucleus accumbens shell (NAcSh) (Li and Kirouac, 2008). These fibers innervate both dopamine D1-receptor and dopamine D2-receptor expressing medium spiny neurons (D1-MSNs and D2-MSNs, respectively) (Zhu et al., 2016; Li et al., 2018) with evidence suggesting that these inputs, when activated, signal stress, aversion, and arousal (Zhu et al., 2016; Ren et al., 2018; Otis et al., 2019). For example, PVT neurons that project to the NAcSh display increased cFos expression levels following acute stress (Bubser and Deutch, 1999). Additionally, footshock or restraint stress exposure reduces inhibitory synaptic transmission onto PVT neurons up to 24 h post stress (Beas et al., 2018). Furthermore, activating PVT excitatory presynaptic terminals in the NAcSh evokes behavioral aversion and induces conditioned place aversion (CPA) (Zhu et al., 2016; Giannotti et al., 2021), whereas heroin administration, which is strongly rewarding, reliably reduces PVT-to-NAc activity (Vollmer et al., 2022).

Negative affective states play a key role in triggering the desire to consume and seek drugs of abuse (Koob, 2008; Koob and Malo, 2008; Koob, 2020). It has been shown that optogenetic activation of the PVT-to-NAc pathway, which drives aversive states (Zhu et al., 2016; Giannotti et al., 2021), significantly increases active lever presses for heroin in a cue-induced reinstatement session (Giannotti et al., 2021). In contrast, inhibition of PVT-to-NAc projections, which would theoretically decrease aversive states, prevents heroin reinstatement (Giannotti et al., 2021). Consistent with this, Keyes et al. used a conditioned place preference (CPP) paradigm to test how inhibiting the PVT-to-NAc pathway affects morphine-induced CPP (Keyes et al., 2020). Using CPP, Keyes et al. conditioned mice with systemic injections of morphine (context 1) or saline (context 2). Following these conditioning sessions, place preference for the morphine-paired context was measured during drug abstinence. It was shown that mice expressed a strong place preference for the
morphine-paired context. However, inhibition of PVT-to-NAc excitatory synaptic transmission blocked morphine-induced CPP (Keyes et al., 2020).

Overall, these results provide evidence that the PVT-to-NAc pathway, when activated, drives aversive states, while, when inhibited, decreases aversive states. However, it remains unknown whether opioids directly act within PVT neurocircuits to drive reward-related phenotypes. Additionally, it remains unknown whether direct inhibition of the PVT-to-NAc pathway in the absence of other stimuli is sufficient to promote reward.

The PVT expresses elevated levels of \( \mu \)-opioid receptors (MORs) (Mansour et al., 1995; Ding et al., 1996; Kolaj et al., 2014; Mengaziol et al., 2022). Application of DAMGO, the selective MOR agonist, induces hyperpolarization of PVT neurons, decreases PVT neuron input resistance, and activates an inwardly rectifying potassium conductance in the presence of tetrodotoxin (TTX) (Brunton and Charpak, 1998; Goedecke et al., 2019). Additionally, using brain slice electrophysiology, bath application of DAMGO suppresses excitatory transmission from the PVT to downstream targets such as the amygdala (Goedecke et al., 2019). Based on these findings, the PVT-to-NAcSh neurocircuit may be a critical pathway that regulates opioid-related reward behaviors. Here, we examine MOR-related effects on the PVT-to-NAcSh neurocircuit using behavioral as well as pathway and cell-type specific approaches.

**MATERIALS AND METHODS**

**Animals**

All experiments were done in accordance with procedures approved by the Pennsylvania State University College of Medicine Institutional Animal Care and Use Committee. Total animal numbers were determined by power analyses (an effect size = 0.5, power = 0.80, and type 1 error (\( \alpha \)) = 0.05). This investigation was not designed to identify sex differences. Therefore, power analysis did not take the number of males and females for each experiment into account. All mice (\( N = 149 \) males = 114; females = 35) used in this study were aged 8-12 weeks at time of recording. Recordings investigating the effects of bath perfused morphine from retrogradely-labeled PVT neurons were conducted in naïve male and female C57BL/6 mice (\( n = 7 \)) (Fig.1).
Cell-type-specific D1-MSNs and D2-MSNs recordings investigating the effects of bath perfused morphine were made using naïve male and female B6 Cg-Tg (Drd1a-tdTomato) line 6 Calak/J hemizygous mice (JAX stock #16204) (n = 4) (Fig. 4). Given that Drd1a-tdTomato transgenic mice have fluorescently labeled D1-MSNs, D2-MSNs were identified based on the lack of fluorescence, cell size, and electrophysiological characteristics, including capacitance and membrane resistance, as previously published (Graziane et al., 2016; McDevitt et al., 2019). Behavioral experiments were performed with male and female C57BL/6 mice, including experiments where morphine was injected directly into the PVT (N = 58) (Fig. 2) and experiments implementing Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) (Fig. 3 (N = 35) and Fig. 5 (N = 43)). Mice were singly housed and maintained on a regular 12 h light/dark cycle (lights on 07:00, lights off 19:00) with ad libitum food and water. Random placement of home cages within the housing and behavioral rooms was employed for electrophysiological and behavioral experiments to control any environmental factors (e.g., room lighting, vibrations) (Steel et al., 2021). 33 mice were excluded from this study due to misplaced cannula (N=2), misplaced or lack of viral expression (Figs. 3; N=12; Fig. 5; N=17), and/or surgical complications (N=2).

**Drugs**

(−)-morphine sulfate pentahydrate (diluted in saline) and clozapine-N oxide (diluted in saline with 0.1% DMSO) were provided by the National Institute on Drug Abuse Drug Supply Program. Picrotoxin was purchased from Sigma Aldrich (Cat. No. P1675). The somatostatin analogue D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) was purchased from Tocris (Cat. No. 1560).

**Stereotaxic Surgery**

Anesthesia was induced and maintained with isoflurane at 1.5%. The animal was placed in a stereotaxic frame (Stoelting, Wood Dale, IL) and craniotomies were performed via microdrill. Injections were carried out via a 33-gauge beveled-tip needle (World Precision Instruments (WPI), Sarasota, FL) connected to a 5 μl Hamilton syringe on a micro pump (Harvard Apparatus, Holliston, MA) at an infusion rate of 200 nL/min. Following injection, the needle was left in situ for 5-10 minutes to allow for virus/tracer diffusion and then slowly retracted to limit backflow. For retrograde labeling experiments, 500 nL of cholera toxin subunit B (CTB) conjugated to Alexa Fluor™ 488 (Invitrogen, Waltham, MA; Cat. # C-22841) diluted in sterile saline was injected into the
medial NAcSh (from Bregma: anterior-posterior (AP): +1.70 mm; medial lateral (ML): ± 0.60 mm; dorsal ventral (DV): -4.50 mm). Mice were used for electrophysiology experiments 3-4 days post-injection. For optogenetic experiments, 200 nL of virus AAV5-CaMKIIa-ChETA (E123T/H134R)-eYFP (Addgene, Watertown, MA; Cat. # 100050; titer: 2.4 x 10^{13} GC/mL) was injected into the midline PVT (from Bregma: anterior posterior (AP): -1.60 mm; medial lateral (ML): ± 0.00 mm; dorsal ventral (DV): -3.30 mm). Midline PVT was targeted as we have shown through electrophysiology approaches that morphine alters the excitability of these neurons (McDevitt and Graziane, 2019) and that the midline PVT projects to the NAcSh (Fig. 1). Mice were used for electrophysiology experiments 4-5 weeks post-injection to allow for virus expression. Mice used for DREADD manipulations were injected with an AAV2-retro engineered serotype (Tervo et al., 2016), pAAV-hSyn-hM4D(Gi)-mCherry (AAVrg) (Addgene; Cat. # 50475-AAVrg; titer: 2.4 x 10^{13}) or pAAV-hSyn-mCherry (AAVrg) (Addgene; Cat. # 114472-AAVrg; titer: 2.4 x 10^{13}) in the NAcSh. For DREADD injections in the PVT, pAAV-hSyn-mCherry (Addgene; Cat. # 114472-AAV5; titer: 8.6 x 10^{12}) and pAAV-hSyn-hM4D(Gi)-mCherry (Addgene; Cat. # 50475-AAV5; titer: 8.6 x 10^{12}). Behavioral experiments occurred 4-5 weeks post-injection to allow for viral expression. Viral vectors were a gift from Karl Deisseroth or Bryan Roth.

**PVT Cannula Procedure**

PVT cannulas were fabricated based on a previously published procedure (Kazanskaya et al., 2020) using a fabricated jig (https://github.com/omn0mn0m/PVT-Cannula-Jig) or purchased (Cat. # C315GA length 2.3 μm; Protech International Inc. (Boerne, Texas)). One week prior to CPP training, mice were implanted with a 26-gauge guide cannula targeting the PVT (from Bregma: AP: -1.60 mm; ML: 0.00 mm; DV: -2.30 mm). On CPP conditioning day, in the absence of anesthesia, saline, morphine (50 ng), or morphine + CTAP (1 ng) (200 nL) was injected through the guide cannula using a 33-gauge needle extending 1 mm past the guide cannula into the PVT (from Bregma: AP: -1.60 mm; ML: 0.00 mm; DV: -3.30 mm) (Cat. # C315IA 33-gauge internal cannula injector 3.3 mm length; Protech International Inc. (Boerne, Texas)) at an infusion rate of 300 nL/min. 1 ng of CTAP was used based on a previous publication (Simmons and Self, 2009). For DREADD experiments, CNO (3 μM, 300 nL) was injected into the PVT at an infusion rate of 300 nL/min as we have shown that this concentration of CNO is sufficient to activate hM4D(Gi)-DREADDs (McKendrick et al., 2022) and others have shown that 3 μM CNO is sufficient to activate hM4D(Gi)-DREADDs in the PVT (Keyes et al., 2020).
**NAcSh Cannula Procedure**

NAcSh cannulas were purchased from PlasticsOne (Roanoke, VA) (Cat. # 8IC235GS512S; length 3.5). One week prior to CPP training, mice were implanted with a 26-gauge guide cannula targeting the NAcSh (from Bregma: AP: +1.70 mm; ML: 0.60 mm; DV: -3.50 mm). On CPP conditioning, in the absence of anesthesia, CNO (3 μM, 500 nL) was injected through the guide cannula using a 33-gauge needle extending 1 mm past the guide cannula into the NAcSh (Cat. # 8IC235IS5SPC, 33-gauge internal cannula injector 3.6 mm length; PlasticsOne (Roanoke, VA)) at an infusion rate of 300 nL/min.

**Cannula Placement**

Cannula placements were checked (Figs. 2, 3, and 5) by injecting 5 mM Evans Blue (MP Biomedicals, LLC; Solon, OH; Cat. # 15108) through the guide cannula. Infusion rates for dye injection were consistent with those used for drug injection during experimentation. Brain slices were then prepared on a Leica VT1200s vibratome to identify the location and diffusion of dye through the tissue.

**Non-contingent Conditioned place preference**

CPP was performed as previously described (McDevitt and Graziane, 2019; McKendrick et al., 2020b; McKendrick et al., 2020a). Briefly, CPP chambers (Med Associates, St. Albans, VT) were in the mouse housing room and consisted of three distinct compartments separated by manual guillotine-style doors. Each compartment had distinct contextual characteristics: the middle (neutral) compartment (7.2 cm × 12.7 cm × 12.7 cm) had grey walls and grey plastic floor, while the choice compartments (16.8 cm × 12.7 cm × 12.7 cm, each) had either white walls and stainless-steel mesh floor or black walls and stainless-steel grid floor. All compartments were illuminated with a dim light during use. Immediately following use the entire preference chamber was cleaned thoroughly with a scent-free soap solution. Mouse locations, activity counts, and time spent in each compartment were collected via automated data-collection software (Med Associates, St. Albans, VT) via infrared photobeam strips lining each compartment.

**Habituation.** Mice were placed in the center compartment with free access to all three compartments for 20 min once a day for two days. Time spent (seconds) in each compartment was recorded.
Conditioning (acquisition phase). 24 h after habituation, mice received 5 d conditioning training. Morphine-paired compartments were assigned based on the least preferred side (Tzschentke, 2007) calculated by averaging time spent in each compartment over the 2 habituation days (Figures 2-1, 3-1, and 5-1). Similar to conditioning studies with alcohol (Gremel et al., 2006), we find that C57BL/6 mice will reliably develop morphine CPP by pairing morphine with the least preferred chamber (McDevitt and Graziane, 2019; McKendrick et al., 2020b; McKendrick et al., 2020a). In this assay, randomly assigning compartments may underestimate the CPP Score, especially when animals are conditioned with an experimental treatment in their preferred chamber. Therefore, a biased design provides a more accurate measurement for these reward-related assays.

At the start of conditioning sessions (09:00), mice received an injection of saline directly in the PVT and were placed into the most preferred compartment (unpaired chamber) for 20 min. After this training session, mice were placed back in their home cage. 4-6 h later (13:00-15:00), mice received an injection of saline (control group), morphine (50 ng, 500 ng, or 5 μg) or morphine (50 ng) + CTAP (1 ng) in the PVT (Fig. 2). The dose range of morphine was determined based on previous studies investigating intracranial effects of morphine (Sharpe et al., 1974; Bozarth and Wise, 1981; David and Cazala, 1994). Experiments investigating the effects of hM4D(Gi) DREADDs consisted of saline or CNO (3 μM) injections directly in the PVT (Fig. 3) or NAcSh (Fig. 5) followed by placement in the most (saline) or least preferred compartment (CNO) (paired chamber) for 20 min. (Koo et al., 2014; Graziane et al., 2016).

Post conditioning (expression phase). One day after the last conditioning day (11:00), mice were placed in the 3-compartment chamber and allowed to move freely for 20 min. CPP scores for both the paired compartments were calculated as time spent in the respective side on test day minus the average time spent on the same side during preconditioning (Bohn et al., 2003). Activity counts are defined as any beam break within a current zone, inclusive of grooming, rearing, and lateral movements.

Acute Brain Slice Preparation
Mice were deeply anesthetized with isoflurane and cardiac perfused with an ice-cold NMDG-based cutting solution containing (in mM): 135 N-methyl-d-glucamine, 1 KCl, 1.2 KH$_2$PO$_4$, 0.5 CaCl$_2$, 1.5 MgCl$_2$, 20 choline-HCO$_3$, and 11 glucose, saturated with 95%O$_2$/5%CO$_2$, adjusted to a pH of 7.4 with HCl, osmolality adjusted to 305 mmol/kg. Following perfusion, mice were decapitated, and brains were rapidly removed. 250 μm coronal brain slices containing the NAcSh or PVT were prepared via a Leica VT1200s vibratome in 4°C NMDG cutting solution. Following cutting, slices were allowed to recover in artificial cerebrospinal fluid (aCSF) containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl$_2$, 1.3 MgCl$_2$, 1 NaH$_2$PO$_4$, 26.2 NaHCO$_3$, and 11 glucose, osmolality of 290 mmol/kg, at 31°C for 30 min followed by 30 min at 20–22°C prior to recording. Slices were kept at 20–22°C for the rest of the recording day.

**Whole-Cell Electrophysiology**

All recordings were made from either the medial NAcSh between Bregma +1.70 mm and +0.86 mm or the middle PVT between Bregma -1.22 and -1.70. Slices were transferred to a recording chamber and neurons were visualized using infrared differential interference contrast microscopy. During recording, slices were superfused with aCSF at 30°C. Where indicated, brain slices were perfused with morphine (10 μM) and/or CTAP (1 μM), the μ-opioid receptor antagonist. Morphine and CTAP concentrations were selected based on previously published findings (Connor et al., 1996; Connor and Christie, 1998; Margas et al., 2010; Mahmoud et al., 2011; Levitt et al., 2015).

For intrinsic membrane excitability (IME) measurements and rheobase measurements recording electrodes [3–5 MΩ; borosilicate glass capillaries (WPI #1B150F-4)] were pulled on a horizontal puller from Sutter Instruments (model P-97) and filled with a potassium-based internal solution containing (in mM): 130 KMeSO$_3$, 10 KCl, 10 HEPES, 0.4 EGTA, 2 MgCl$_2$-6H$_2$O, 3 Mg-ATP, 0.5 Na-GTP, pH 7.2–7.4, osmolality = 290 mmol/kg (Wescor Vapro Model 5,600, ElitechGroup).

Resting membrane potential was recorded immediately following break-in. For IME experiments, we employed a commonly used current step protocol (Ishikawa et al., 2009; McDevitt and Graziane, 2019; McDevitt et al., 2019; Roselli et al., 2020). In this study, the IME and rheobase protocols were conducted at unadjusted resting
membrane potentials. Our current step protocol, consisting of 1 s steps ranging from −100 to 100 pA in 50 pA increments, was carried out with a 20 s intra-sweep interval. The number of action potentials observed at each current step was recorded. For rheobase experiments, a 2 s consistent-slope current injection ramp with a maximal current of 400 pA was performed, as previously described (Pati et al., 2020). The rheobase was defined as the minimal current needed to elicit an action potential.

For recording optically-evoked excitatory postsynaptic currents (oEPSCs), in the NAcSh, recording electrodes (3–5 MΩ; borosilicate glass capillaries WPI #1B150F-4) were pulled on a horizontal puller from Sutter Instruments and filled with a cesium-based internal solution (in mM): 135 CsMeSO\textsubscript{3}, 5 CsCl, 5 TEA-Cl, 0.4 EGTA (Cs), 20 HEPES, 2.5 Mg-ATP, 0.25 Na-GTP, 1 QX-314 (Br), pH 7.2–7.4, osmolality = 290 mmol/kg. To evoke optical excitatory postsynaptic currents (oEPSCs), PVT presynaptic afferents were stimulated at 0.1 Hz by flashing 470 nm light (0.1–0.3 ms duration) through the light path of the microscope using an LED-based light source (X-Cite 120LED Boost, Excelitas Technologies Corp). Following cell stabilization after break-in, a stable baseline of 30-50 AMPA-mediated oEPSCs were obtained at -70 mV command voltage. The AMPA-mediated peak amplitude was determined by measuring the amplitude of oEPSCs at -70 mV command voltage. Paired pulse recordings were performed with two optically-evoked stimuli separated by 50 ms.

All recordings were performed using either an Axon Multiclamp 700B amplifier or Sutter Double IPA, filtered at 2–3 kHz, and digitized at 20 kHz. Series resistance was typically 10–25 MΩ, left uncompensated, and monitored throughout. For all voltage-clamp recordings, cells with a series of resistance variation greater than 20% were discarded from the analysis. For all current-clamp recordings, cells with a bridge balance that varied greater than 20% during the start and end of recordings were discarded from analysis. Percent change was calculated as ((Final Value - Baseline Value) / Absolute Baseline Value) x 100.

**Statistical Analysis**

All results are shown as mean ± SEM. Data sets were tested for normality and equality of variances and the appropriate statistical measures were performed. Statistical significance was assessed in GraphPad Prism software using a paired Student’s t-test, one- or two-way ANOVA with Bonferroni’s correction for multiple
comparisons to identify differences as specified. F-values for two-way ANOVA statistical comparisons represent interactions between variables unless otherwise stated. Two-tailed tests were performed for all studies. The effect sizes for group comparisons were quantified using Cohen’s $d$, which expresses the magnitude of the difference between group means in terms of standard deviations (Sullivan and Feinn, 2012).

RESULTS

**Bath application of morphine reduces excitability in PVT neurons that project to the NAcSh**

We first investigated whether morphine directly influenced the neuronal excitability of PVT neurons that project to the NAcSh. To do this, we retrogradely labeled PVT neurons by injecting CTB-488 into the NAcSh. This permitted CTB to be taken up into the cytoplasm of PVT afferents that innervate the NAcSh, resulting in fluorescently labeled PVT neurons 3-4 days later (Fig. 1A). 3-4 days after CTB injections, brain slices containing the PVT were prepared for whole-cell electrophysiology recordings. Fluorescently labeled PVT neurons were current-clamped and recorded in the absence (aCSF) and presence of bath perfused morphine (10 $\mu$M). We observed that upon bath application of morphine, the resting membrane potential of PVT neurons that project to the NAcSh was significantly hyperpolarized ($t(7) = 3.03; p = 0.0192$; paired Student’s $t$-test) (Fig. 1B). To investigate whether this effect was mediated by activation of $\mu$-opioid receptors, we bath applied morphine in the presence of CTAP (1 $\mu$M), the selective $\mu$-opioid receptor antagonist, and observed no significant change in the RMP ($t(9) = 1.338; p = 0.2138$; paired Student’s $t$-test) (Fig. 1C). Additionally, we found a significant decrease in the percent change of the RMP following bath application of morphine in absence compared to the presence of CTAP ($t(16) = 3.475; p = 0.0031$; Student’s $t$-test) (Fig. 1D), suggesting that morphine-induced hyperpolarization of PVT neurons is mediated through $\mu$-opioid receptors.

Next, we investigated the effects of morphine on the rheobase, the minimum current required to evoke an action potential, in PVT neurons that project to the NAcSh. Increases in the rheobase suggest an increased threshold for neuronal excitability, indicating that the neuron has become less responsive to current input. Conversely, decreases in the rheobase suggest a lowered threshold for neuronal excitability, indicating that the neuron has become more responsive to a stimulus. We found that in the presence of morphine, the rheobase
was significantly increased \(t(7) = 3.557; \ p = 0.0093\); paired Student’s \(t\)-test) (Fig. 1E). Furthermore, we observed that the effects of morphine were mediated through \(\mu\)-opioid receptors as CTAP prevented morphine-induced changes \(t(9) = 0.6186; \ p = 0.5515\); paired Student’s \(t\)-test) (Fig. 1F) and blocked morphine-induced increases in the rheobase \(t(16) = 2.521; \ p = 0.0227\); Student’s \(t\)-test) (Fig. 1G).

Lastly, we measured the intrinsic membrane excitability in PVT neurons that project to the NAcSh in the presence of morphine. We found that the intrinsic membrane excitability was significantly decreased \(F_{(10,120)} = 7.840; \ p < 0.0001\); Two-way repeated measures ANOVA with Bonferroni post-test) (Fig. 1H) and this morphine-induced effect was blocked by CTAP (80 pA: mor. vs. mor. + CTAP: \(p = 0.0194\); aCSF vs. mor. + CTAP: \(p > 0.9999\); Bonferroni post-test) (Fig. 1H). Overall, our observed morphine-induced inhibition of PVT neurons is consistent with what has been observed with DAMGO, an MOR agonist (Brunton and Charpak, 1998).

\(\mu\)-opioid receptor activation in PVT neurons that project to the NAcSh is sufficient to evoke opioid reward

Given the evidence that activation of PVT-to-NAC synaptic transmission evokes aversive behaviors (Bubser and Deutch, 1999; Zhu et al., 2016; Beas et al., 2018), we next investigated whether the inhibitory actions of morphine in the PVT were sufficient to evoke opioid reward. To test this, we performed CPP experiments, as CPP is reliably used to measure the rewarding properties of drugs (McKendrick and Graziane, 2020). Mice underwent CPP training consisting of two habituation days, followed by five days of conditioning, and CPP was measured on post conditioning day 1 (Fig. 2A). Saline (equal volume, i.c.) or varying doses of morphine (50 ng, 500 ng, 5 \(\mu\)g, i.c.) were injected directly into the PVT during conditioning sessions with cannula placements verified after experimentation (Extended Data Figure 2-2). We found that mice conditioned with morphine (50 ng, i.c.) displayed preference for the morphine-paired chamber \(F_{(3,30)} = 3.051, \ p = 0.0436\); one-way ANOVA with Bonferroni post-test) (saline vs. morphine (50 ng): \(p = 0.0471\), Cohen’s \(d = 1.92\); saline vs. morphine (500 ng): \(p = 0.6117\), Cohen’s \(d = 0.829\); saline vs. morphine (5 \(\mu\)g): \(p = 0.3706\), Cohen’s \(d = 0.857\); morphine (50 ng) vs. morphine (500 ng): \(p > 0.9999\), Cohen’s \(d = 0.583\); morphine (50 ng) vs. morphine (5 \(\mu\)g): \(p > 0.9999\), Cohen’s \(d = 0.451\); morphine (500 ng) vs. morphine (5 \(\mu\)g): \(p > 0.9999\).
Cohen’s $d = 0.065$ (Fig. 2B and Extended Data Table 2-3). To test whether morphine (50 ng)-induced CPP was caused by $\mu$-opioid receptor activation, we repeated CPP experiments by conditioning separate groups of mice with saline (i.c. in PVT) or 50 ng of morphine in the absence and presence of CTAP (1 ng, i.c. in PVT). The results show that in the presence of CTAP, morphine (50 ng i.c. in the PVT)-induced CPP was blocked ($F_{(2,21)} = 6.149, p = 0.0079$; one-way ANOVA with Bonferroni post-test) (saline vs. mor.: $p = 0.0110$; mor. vs. mor. + CTAP: $p = 0.0376$; Bonferroni post-test) (Fig. 2C) suggesting that morphine injected into the PVT evokes CPP through $\mu$-opioid receptor activation.

In addition to measuring CPP, we monitored locomotor activity following morphine delivery directly in the PVT as significant increases in locomotor activity are observed following systemic injection of morphine in C57BL/6 mice (Graziane et al., 2016; McKendrick et al., 2020b; McKendrick et al., 2020a). To do this, we measured activity counts defined as any beam break within a current zone, inclusive of grooming, rearing, and lateral movements. Activity counts were measured during each conditioning session (conditioning day 1-5) in the absence (unpaired chamber) or presence (paired chamber) of morphine injections in the PVT. Our results show that morphine at all doses administered had no effect on the activity counts during conditioning sessions ($F_{(27,162)} = 1.547, p = 0.0519$; two-way repeated measures ANOVA) (Fig. 2D).

Lastly, systemic injections of escalating doses of morphine have been shown to reduce locomotor activity 24 h after the last exposure, which is associated with spontaneous opioid withdrawal (Madayag et al., 2019; McDevitt et al., 2021). Because of this, we compared activity of mice before conditioning sessions (habituation) with activity of mice after morphine exposure (test). If mice were undergoing spontaneous opioid withdrawal, a significant decrease in locomotor activity would be expected to occur during the post conditioning test compared to locomotor activity observed during habituation. Our results show that morphine (50 ng, 500 ng, or 5 $\mu$g) injected directly into the PVT did not alter activity counts 24 h after the last conditioning day ($F_{(4,26)} = 0.7325, p = 0.5758$; two-way repeated measures ANOVA) (Fig. 2E).

Morphine inhibits neuronal activity through $G_{i/o}$-protein coupled receptor signaling and subsequent opening of potassium channels (Koski and Klee, 1981; Williams et al., 1982; Hsia et al., 1984; Schroeder et al., 1999).
Our results show that morphine decreases neuronal excitability of PVT neurons that project to the NAcSh (Fig. 1). Additionally, our results show that morphine injected directly into the PVT is associated with the acquisition of opioid context associations (Fig. 2). Therefore, we next investigated whether inhibiting PVT neurons that project to the NAcSh, using chemogenetic approaches (Urban and Roth, 2015), mimicked the rewarding effects of morphine. For these experiments, we employed a retrograde hM4Di-DREADD, which when stimulated by clozapine-N-oxide (CNO), activates G-protein inwardly rectifying potassium channels (GIRKs) resulting in hyperpolarization and attenuation of neuronal activity (Armbruster et al., 2007). The retrograde hM4Di-DREADD was injected bilaterally into the NAcSh, permitting retrograde transport of the hM4Di-DREADD to the PVT via PVT afferents in the NAcSh (Fig. 3A and B). A cannula was implanted in the PVT for local delivery of CNO and cannula placements were verified after experimentation (Extended Data Figure 3-2). Mice underwent CPP training consisting of two habituation days, followed by five days of conditioning where saline (equal volume, i.c.) or CNO (3 µM, i.c.) was injected directly into the PVT, and CPP was measured on postconditioning day 1. We found that hM4Di-expressing mice conditioned with CNO (3 µM, i.c.) displayed CPP for the CNO-paired chamber compared to control mice ($F_{(1,31)} = 4.370$, $p = 0.045$; two-way ANOVA with Bonferroni post-test) (mCherry(sal) vs. mCherry(CNO): $p > 0.9999$, Cohen’s $d = 0.001$; mCherry(sal) vs. hM4Di(sal): $p > 0.9999$, Cohen’s $d = 0.110$; mCherry(sal) vs. hM4Di(CNO): $p = 0.0853$, Cohen’s $d = 1.23$; mCherry(CNO) vs. hM4Di(sal): $p > 0.9999$, Cohen’s $d = 0.132$; mCherry(CNO) vs. hM4Di(CNO): $p = 0.0612$, Cohen’s $d = 1.47$; hM4Di(sal) vs. hM4Di(CNO): $p = 0.0384$, Cohen’s $d = 1.84$) (Fig. 3C and Extended Data Tables 3-3 and 3-4).

**Bath application of morphine reduces excitatory postsynaptic currents (EPSCs) at PVT-to-D1-MSN and PVT-to-D2-MSN synapses**

Thus far, our results suggest that inhibition of PVT neurons that project to the NAcSh is an important pathway involved in mediating the acquisition of reward-related context associations. However, PVT axons are known to bifurcate with one neuron sending axons to multiple brain regions (Li et al., 2021; Viena et al., 2022). Therefore, we next investigated the inhibitory effects of morphine directly on PVT-to-NAcSh synapses using brain slice electrophysiology approaches. For these experiments, the channelrhodopsin mutant, ChETA, was injected into the PVT of Drd1a-tdTomato mice, permitting ChETA expression on PVT afferents in the NAcSh.
(Fig. 4A). Drd1a-tdTomato mice were used to assess cell-type specific synaptic alterations in the NAcSh (Adet et al., 2011) through investigations on D1-MSNs and D2-MSNs, the main output neurons of the NAcSh (McDevitt and Graziane, 2018). Whole-cell voltage clamp recordings were performed on D1- or D2-MSNs and optically evoked EPSCs were recorded at PVT-to-D1-MSN or PVT-to-D2-MSN synapses. The magnitude of morphine-induced decrease in optically-evoked EPSCs (oEPSCs) was determined as the mean oEPSC peak amplitude 2 min just before morphine application compared with mean oEPSC peak amplitude during the final 2-min period of morphine application, corresponding to trials 48-60 (Fig. 4B). Our results show that bath application of morphine (10 μM) significantly reduced the optically evoked current at both PVT-to-D1-MSNs ($t_{16} = 9.546; p < 0.001$; paired Student’s $t$-test) (Figs. 4B and C) and PVT-to-D2-MSN synapses ($t_{12} = 8.539; p < 0.001$; paired Student’s $t$-test) (Figs. 4B and D). We also observed that this morphine-induced decrease was not significantly different at PVT-to-D1-MSN versus PVT-to-D2-MSN synapses ($t_{14} = 0.8335; p = 0.4186$; paired Student’s $t$-test) (Fig. 4E), suggesting that morphine inhibits PVT neurotransmission similarly at both D1- and D2-MSNs.

To identify whether morphine inhibits PVT-to-MSN synaptic transmission through pre or postsynaptic mechanisms, we measured the paired pulse ratio, whereby the peak amplitude of the second pulse was divided by the peak amplitude of the first pulse. An increase in the paired pulse ratio is associated with presynaptic inhibition, a decrease in the ratio is associated with presynaptic potentiation, and no change in the paired-pulse ratio reflects a postsynaptic modification (Creager et al., 1980; Harris and Cotman, 1983; Brundege and Williams, 2002). We observed no significant change in the paired pulse ratio during bath application of morphine at PVT-to-D1-MSN ($t_{8} = 1.204; p = 0.2629$; paired Student’s $t$-test) (Figs. 4F and G) or PVT-to-D2-MSN synapses ($t_{8} = 0.445; p = 0.6720$; paired Student’s $t$-test) (Figs. 4F and H). However, in analyzing spontaneous EPSCs (sEPSCs), which are inclusive of all glutamatergic inputs in the NAcSh, we found that morphine significantly decreased sEPSC frequency with no effect on sEPSC amplitude when recording from D1-MSNs (Frequency: $t_{6} = 4.055; p = 0.0067$; paired Student’s $t$-test; Amplitude: $t_{6} = 0.4487; p = 0.6694$; paired Student’s $t$-test) (Figs. 4I, J, and K) or D2-MSNs (Frequency: $t_{6} = 3.959; p = 0.0075$; paired Student’s $t$-test; Amplitude: $t_{6} = 0.7256; p = 0.4954$; paired Student’s $t$-test) (Figs. 4I, L, and M). Given that changes in sEPSC frequency are associated with presynaptic modifications and changes in sEPSC amplitude...
are associated with postsynaptic modifications, these results suggest that circuit specific modifications account for morphine-induced inhibition in the NAcSh.

Our results suggest that morphine decreases synaptic transmission at PVT-to-NAcSh projecting neurons, but whether inhibiting PVT synaptic transmission in the NAcSh is involved in the acquisition of context associations remains unknown. Therefore, we next investigated whether direct inhibition of PVT to NAcSh synaptic transmission was sufficient to evoke reward-related context associations. For these experiments, hM4Di-DREADD was injected into the PVT (Fig. 5A). A guide cannula was implanted in the NAcSh for local delivery of CNO (verified after experimentation (Extended Data Figure 5-2)), thus permitting hM4Di-DREADD activation on PVT presynaptic terminals in the NAcSh (Fig. 5B). Mice underwent CPP training consisting of two habituation days, followed by five days of conditioning where saline (equal volume, i.c.) or CNO (3 μM, i.c., 500 nL) was injected directly into the NAcSh during conditioning sessions, thereby inhibiting PVT synaptic transmission. CPP was measured on postconditioning day 1. We found that hM4Di-expressing mice conditioned with CNO (3 μM, i.c.) displayed no significant CPP for the CNO-paired chamber compared to control mice ($F_{(1,38)} = 2.400, p = 0.1297$; two-way ANOVA) (mCherry(sal) vs. mCherry(CNO): $p > 0.9999$, Cohen’s $d = 0.050$; mCherry(sal) vs. hM4Di(sal): $p > 0.9999$, Cohen’s $d = 0.204$; mCherry(sal) vs. hM4Di(CNO): $p = 0.5417$, Cohen’s $d = 0.983$; mCherry(CNO) vs. hM4Di(sal): $p > 0.9999$, Cohen’s $d = 0.291$; mCherry(CNO) vs. hM4Di(CNO): $p = 0.6626$, Cohen’s $d = 1.17$; hM4Di(sal) vs. hM4Di(CNO): $p = 0.2312$, Cohen’s $d = 1.23$) (Fig. 5 and Extended Data Tables 5-3 and 5-4).

Finally, we observed differences in the variability of data presented in Figures 3 and 5 among the experimental groups (hM4Di(CNO)-PVT vs. hM4Di(CNO)-NAcSh). We conducted an analysis to explore the variance in the CPP scores between these two groups. We observed a significant difference in the variance of the CPP score between mice with inhibition of PVT neurons that project to the NAcSh (Fig. 3) versus mice with inhibition of PVT presynaptic terminals in the NAcSh (Fig. 5) ($F_{(8,7)} = 7.631; p = 0.0146$; unpaired Student’s $t$-test with an $F$ test to compare variances).

**DISCUSSION**
Here, we show that morphine inhibits PVT neurons that project to the NAcSh and reduces synaptic transmission at both PVT-to-D1-MSN and PVT-to-D2-MSN synapses in the NAcSh. Additionally, we provide evidence that the PVT is necessary for the acquisition of morphine CPP as direct injections of morphine in the PVT resulted in place preference for the morphine-paired chamber.

Recent reports have shown that morphine and DAMGO reduce PVT neuron firing rates, that DAMGO hyperpolarizes amygdala-projecting PVT neurons, that DAMGO inhibits glutamatergic synaptic transmission at PVT-to-MSNs in the NAc, and that heroin reduces the activity of PVT-to-NAc neurons (Goedecke et al., 2019; Vollmer et al., 2022; Hou et al., 2023). Our results are consistent with these findings as we show that PVT neurons that project to the NAcSh express hyperpolarized resting membrane potentials, increases in rheobase, and decreases in the intrinsic membrane excitability upon bath perfusion of morphine (Fig. 1). The hyperpolarizing effects of MOR agonists on PVT neurons is not surprising considering that MOR activation results in the activation of inwardly rectifying potassium channels (Zamponi and Snutch, 1998; Torrecilla et al., 2002; Torrecilla et al., 2008), thus causing positively charged K+ ions to move from the intracellular to extracellular space, leading to hyperpolarization of the membrane potential.

Not only did morphine inhibit neuronal excitability of PVT neurons that projected to the NAcSh, but morphine also inhibited synaptic transmission at both PVT-to-D1- and D2-MSN synapses in the NAcSh. However, more studies are required to elucidate the pre and/or postsynaptic mechanisms mediating this inhibitory effect. Given that MORs are expressed on PVT neurons, it would be expected that MOR activation on PVT terminals in the NAcSh would result in reduced presynaptic neurotransmitter release. This change in presynaptic release can be measured using electrophysiological approaches like the paired pulse ratio. During bath application of morphine, we did not observe a significant change in the paired pulse ratio at PVT-to-D1-MSN or PVT-to-D2-MSN synapses, as both the first and second pulse were inhibited similarly by morphine. However, when analyzing spontaneous excitatory postsynaptic currents (sEPSCs), inclusive of all glutamatergic inputs projecting to the NAcSh, we observed a significant decrease in sEPSC frequency in the presence of bath-applied morphine. Changes in sEPSC frequency support a presynaptic modification. In contrast, we did not observe a significant change in the sEPSC amplitude, which is commonly associated with
postsynaptic modifications. The typical mechanisms of opioid-receptor-mediated neurotransmission involve presynaptic modulation of neurotransmitter release or postsynaptic modulation of voltage-gated channels (Reeves et al., 2022). The internal solution used in our recordings included voltage-gated channel blockers, enabling us to isolate synaptically-mediated currents. Therefore, our results suggest that PVT-to-MSN synapses in the NAcSh possess a unique response to morphine that may include postsynaptic modulation of synaptically-expressed receptors. In line with this, Zhu et al. demonstrated that chronic morphine treatment and in vivo optogenetic long-term depression did not affect the paired-pulse ratio of MSNs receiving PVT input (Zhu et al., 2016).

Evidence suggests that activation of the PVT and its afferents in the central amygdala and nucleus accumbens leads to aversive behaviors (Penzo et al., 2015; Zhu et al., 2016; Zhou et al., 2022). Therefore, one may expect that inhibition of the PVT, via MOR activation, would result in reward-related behavioral phenotypes. Here, we show that the morphine-induced inhibition of PVT neurons is sufficient to generate the acquisition of CPP following direct injections of morphine into the PVT (Fig. 2). However, this effect was only observed with 50 ng (330 μM) of morphine and not with morphine injections of 500 ng (3.30 mM) or 5 μg (33.0 mM). Given that morphine is a weak agonist at kappa opioid receptors (K_I = ~115 nM) (Ben Haddou et al., 2014; Miyazaki et al., 2017), this may be due to off target activation at kappa opioid receptors, which are expressed in the PVT (Le Merrer et al., 2009). Future experiments will look to see whether co-infusing these higher morphine doses with a kappa opioid receptor antagonist can “un-mask” CPP. Notably, we found that morphine-injections directly into the PVT had no effect on locomotor activity, suggesting that the PVT is not associated with the locomotor sensitization often observed after systemic morphine injection in C57BL/6 mice (Walters et al., 2005; Contet et al., 2008; Guegan et al., 2016; Bulin et al., 2020; Leite Júnior et al., 2023). Locomotor sensitization is highly dependent on the context in which the drug is administered (Robinson and Berridge, 2003), thus it is possible in another context we might observe a sensitized response to acute morphine injections in the PVT. However, similar results were obtained when PVT projections to the central amygdala were inhibited and no effect on locomotor sensitization evoked by systemic morphine injections was observed (Keyes et al., 2020). Additionally, this same study found that optical activation of PVT neurons that project to the central amygdala had no effect on locomotor activity (Keyes et al., 2020).
Our findings also show that chemogenetic inhibition of PVT neurons that project to the NAcSh mimics morphine’s effects on the acquisition of context associations (Fig. 3). However, it is known that ventromedial NAcSh-projecting PVT neurons (our targeted region) bifurcate sending collateral projections to brain regions involved in the acquisition of context associations like the central amygdala (Dong et al., 2017; Li et al., 2021). Therefore, when inhibiting PVT neurons that project to the NAcSh, we were also potentially inhibiting collateral projections to other brain regions, thus contributing to a robust increase in place preference. Future studies will need to investigate these projection-specific effects.

Interestingly, although we did see a significant increase in the CPP score during somatic inhibition of PVT neurons that project to the NAcSh (Fig. 3), this outcome was not observed when we directly inhibited PVT presynaptic terminals in the NAcSh (Fig. 5). These results suggest that acquisition of CPP, which entails, in part, learning and memory and reward, is not solely dependent upon PVT-to-NAcSh signaling, but may require the inclusion of other PVT signaling pathways in addition to or in the absence of PVT-to-NAcSh signaling. Prior studies have demonstrated that chemogenetic inhibition of midline PVT-to-NAcSh pathway in conjunction with systemic morphine exposure does not prevent the acquisition of morphine-induced conditioned place preference (Keyes et al., 2020). However, the interpretation of these findings remains challenging, as it is unclear whether the observed lack of effect is due to an occlusion effect (chemogenetic inhibition is ineffective due to concurrent inhibition by morphine) or if PVT-to-NAcSh neurotransmission is genuinely not required for the acquisition of morphine-induced CPP. Our findings suggest that midline PVT neurotransmission in the NAcSh is not required for the acquisition of CPP. Despite this, there does appear to be a key role of PVT-to-NAcSh signaling in motivational states. It was shown that chemogenetic inhibition of midline PVT-to-NAcSh neurotransmission following the acquisition of morphine CPP (i.e., conditioning sessions) blocked the expression of morphine-induced CPP (Keyes et al., 2020). Additionally, it was shown that activation of posterior PVT-to-NAcSh was sufficient to drive heroin reinstatement after abstinence (Giannotti et al., 2021). Interestingly, midline PVT-to-NAc stimulation promotes wakefulness (Ren et al., 2018) and blocking dopamine-induced neuromodulation in the NAc abolishes locomotor effects of opioids (Stinus et al., 1980; Kalivas et al., 1983). Based on our findings and those of others, it is plausible to speculate that PVT-to-NAcSh
neurotransmission along with neuromodulation by dopamine promotes arousal, which is required for reward-seeking behaviors.

There is another possible explanation for why inhibiting PVT terminals in the NAcSh was not sufficient to evoke CPP (Fig. 5). We observed a significant difference in the variance of the CPP score between mice with inhibition of PVT neurons that project to the NAcSh (Fig. 3) versus mice with inhibition of PVT presynaptic terminals in the NAcSh (Fig. 5). The significant increase in the CPP score’s variance in mice with inhibition of PVT presynaptic terminals in the NAcSh suggests that there is a heterogeneous neuronal population that contributes to various facets of the behavioral output. It is known that the PVT sends projections to the NAcSh that target different neuronal populations, including D1-MSNs, D2-MSNs, and interneurons, including parvalbumin interneurons (Zhu et al., 2016; Vollmer et al., 2022). D1- and D2-MSNs both innervate the ventral pallidum, however, D1-MSNs innervate the lateral hypothalamus, ventral tegmental area, and substantia nigra (Heimer et al., 1991; Usuda et al., 1998; Zhou et al., 2003; Tripathi et al., 2010; O’Connor et al., 2015; Yang et al., 2018). Likewise, interneurons within the NAcSh are well-positioned to modulate both D1- and D2-MSN function and regulate behavioral outcomes (Witten et al., 2010; Brown et al., 2012; Qi et al., 2016; Yu et al., 2017). These connectivity discrepancies potentially explain why inhibition of PVT presynaptic terminals in the NAcSh, in the absence of direct cell-type specific manipulations, results in heterogenous behavioral outcomes when measuring the acquisition of reward-related context associations. In line with this, microinjections of morphine into the NAc have yielded inconsistent findings, as one study reported place preference (van der Kooy et al., 1982), while another indicated no such preference (Olmstead and Franklin, 1997). These contrasting results may be due to opioid-induced inhibition of specific regions in the NAc or neuronal populations.

Based on our findings and those of others, it is tempting to simplify the role of the PVT in reward processing by stating that when activated, the PVT evokes aversive behaviors and when inhibited, the PVT generates behaviors associated with positive reinforcement. However, reward processing encompasses a multitude of complex neural and behavioral functions that are regulated by the PVT, including arousal/wakefulness (Gent et al., 2018; Ren et al., 2018; Wang et al., 2021; Eacret et al., 2023), stress (Penzo
et al., 2015; Öz et al., 2017; Bengoetxea et al., 2020; Dong et al., 2020; Yu et al., 2021; Corbett et al., 2022a; Corbett et al., 2022b), learning and memory (Hamlin et al., 2009; Li et al., 2011; Browning et al., 2014; Haight et al., 2015; Otis et al., 2017; Otis et al., 2019; Keyes et al., 2020), prediction (Munkhzaya et al., 2020), and reinforcement (Marchant et al., 2010; Matzeu et al., 2015; Labouèbe et al., 2016; Zhang and van den Pol, 2017; Cheng et al., 2018; Giannotti et al., 2018; Kuhn et al., 2018; Campus et al., 2019; Lafferty et al., 2020; Matzeu and Martin-Fardon, 2020; Chisholm et al., 2021; Giannotti et al., 2021; Kessler et al., 2021; Vollmer et al., 2022; Brown and Chaudhri, 2023). Therefore, it is more likely that the role of the PVT in reward processing is nuanced and multifaceted, depending upon the specific stage of reward learning, the type of reward (natural or drug-related), the PVT region (e.g., anterior, middle, posterior), the PVT cell type (Gao et al., 2023), and the brain regions that the PVT interacts with. This has been elegantly demonstrated by a recent study showing the role that the PVT plays in mediating the balance between behaviors associated with seeking reward and those associated with avoiding danger (Choi and McNally, 2017). The study found that the chemogenetic suppression of the PVT results in a behavioral bias towards either defensive or rewarding responses, depending on the specific experimental conditions, without consistently favoring one response over the other (Choi and McNally, 2017). These results support the complex role of the PVT in regulating the balance between behaviors associated with seeking rewards and those associated with avoiding danger.

Limitations

Our findings do not come without limitations. First, although female mice were used throughout the study, we were unable to include sufficient numbers of female mice to perform statistical comparisons between males and females. Second, the discrepancies observed between somatic inhibition of PVT neurons that project the NAcSh (Fig. 3) versus PVT terminal inhibition in the NAcSh (Fig. 5) are potentially explained by technical limitations. For example, off target CNO DREADD(Gi) activation of PVT terminals in the NAc core may have contributed to our non-significant findings (Figure 5). However, this is unlikely as PVT neurons that project to the NAc core are less numerous than those to the NAcSh (Dong et al., 2017) and our trypan blue procedure showed minimal NAc core staining. Additionally, evidence suggests that the non-specific effects can occur from specific AAV serotypes (Haery et al., 2019). For example, AAV1 and AAV9 demonstrate anterograde transsynaptic transport at high titers (Zingg et al., 2017). Here, an AAV2-retro engineered
serotype was employed with no evidence of this serotype possessing anterograde transport. Therefore, it is unlikely that any non-specific transport took place in the data presented in Figure 3. However, if non-specific transport were to take place, guide cannula directed CNO injections targeting the PVT would minimize any potential confounds caused by non-specific transport. Lastly, our investigation focused on midline PVT projections to the NAcSh and did not investigate the effects of the anterior or posterior PVT in the formation and expression of context associations. These investigations are required in order to fully comprehend an understanding of PVT function.

Conclusions

It is known that the acquisition of drug-context associations relies on the coordinated activity of many different brain regions, including those involved in signaling salient cues (ventral tegmental area and nucleus accumbens), contributing to affective, emotion, and cognitive control (amygdala, insula, prefrontal cortex, and anterior cingulate cortex), signaling sensation (somatosensory cortex), and processing spatial information and memory (hippocampus) (McKendrick and Graziane, 2020). These results establish the PVT as a brain region situated within a complex neurocircuit that mediates the acquisition of opioid context associations and provide evidence that inhibition of PVT neurons is associated with reward.

Overall, this is one of the first studies to examine the direct effects of PVT inhibition on reward-related behaviors through manipulations related to drugs of abuse (morphine) and through chemogenetic approaches that mimic morphine-induced effects. Future experiments could manipulate specific PVT projection neurons, including those that express MORs, and identify behavioral outcomes following either activation or inhibition of these neuronal subtypes. These continued manipulations of PVT neurons will help guide our understanding of the dynamic activity of the PVT as it integrates signals related to reward, danger, and arousal.

Author Contributions

DSM, JAB, and NMG designed the experiments. DSM, GEM, QWW, JN, MS, NT, and NMG collected data and performed the analyses. DSM, QWW, JAB, and NMG wrote the manuscript.
**Figure 1.** Bath application of morphine hyperpolarizes PVT neurons that project to the NAcSh in C57BL/6 wild-type mice. (A) (Left) Illustration of CTB injections in the NAcSh with recordings taking place in the PVT. (Right) DIC and fluorescent images showing CTB injections in the NAcSh and fluorescently labeled neurons in the PVT. (B) Graph showing the resting membrane potential (RMP) of individual PVT neurons that project to the NAcSh before (aCSF) and after (Mor) bath application of morphine (10 μM) (8 neurons/5 mice: 3 males, 2 females). (C) Graph showing the RMP of individual PVT neurons that project to the NAcSh before (aCSF) and after (Mor+CTAP) bath application of morphine (10 μM) in the presence of CTAP (1 μM) (10 neurons/3 male mice). (D) Graph showing the percent decrease in the RMP from baseline following morphine or morphine + CTAP. (E) Representative traces (top) and graph showing the rheobase of individual neurons before and after bath application of morphine (10 μM) (9 neurons/5 mice: 3 males, 2 females). Scale bars: 40 mV, 800 ms. (F) Representative traces (top) and graph showing the rheobase of individual neurons before and after bath application of morphine (10 μM) + CTAP (1 μM) (10 neurons/3 male mice). Scale bars: 25 mV, 250 ms. (G) Graph showing the percent decrease in the rheobase from baseline following morphine or morphine + CTAP. (H) Representative traces (left) and summary graph showing the number of action potentials fired in PVT neurons that project to the NAcSh is significantly decreased following bath application of morphine (10 μM), which was blocked in the presence of CTAP. Scale bars: 25 mV, 100 ms. aCSF (open circles): n = 11 neurons/5 mice (3 males, 2 females); Mor (dark gray circles): n = 7 neurons/5 mice (3 males, 2 females); Mor.+CTAP (light gray circles): n = 9 neurons/3 male mice. *p < 0.05; **p < 0.01

**Figure 2.** Direct application of morphine in the PVT permits CPP. (A) Experimental timeline and drug regimen for the behavioral procedure (Extended Data Figure 2-1). (B) Summary graph showing that morphine (50 ng, i.c.) injected directly into the PVT produced CPP (saline: n = 12 male mice; morphine (50 ng): n = 7 male mice; morphine (500 ng): n = 7 male mice; morphine (5 μg): n = 8 male mice) (Extended Data Figure 2-2 and Table 2-3). (C) Summary graph showing that co-administration of CTAP (1 ng) with morphine (50 ng) in the PVT blocked CPP (saline: n = 8 male mice; morphine (50 ng): n = 8 male mice; morphine (50 ng) + CTAP: n = 8 male mice). (D) Summary graph showing activity counts during conditioning. a = unpaired chamber, b = paired
chamber (saline: n = 4 male mice; 50 ng morphine: n = 5 male mice; 500 ng morphine: n = 6 male mice; 5 μg morphine: n = 7 male mice). (E) Summary graph showing activity counts before conditioning and 24 h after the last conditioning day (saline: n = 10 male mice; morphine (50 ng): n = 7 male mice; morphine (500 ng): n = 7 male mice; morphine (5 μg): n = 7 male mice). *p < 0.05

**Figure 3.** Inhibition of PVT projections to the NAcSh evokes CPP. (A) Experimental timeline and drug regimen for the behavioral procedure (Extended Data Figure 3-1). PVT cannulated mice were injected with retrograde-mCherry or retrograde-hM4di in the NAcSh (Extended Data Figure 3-2). (B) Summary demonstrating viral injection placements in retrograde-mCherry and retrograde-hM4di-expressing mice. (Right) A representative image of viral expression in the PVT 6 weeks following viral injection of retrograde viral constructs in the NAcSh. Scale bar: 200 μM. (C) Summary graph showing the CPP score in mice conditioned with saline (equal volume) or CNO (3 μM) injected directly into the PVT (mCherry-sal: n = 4/4 (male/female); mCherry-CNO: n = 10 (male/female); hM4di-sal: n = 5/4 (male/female); hM4di-CNO: n = 6/2 (male/female)) (Extended Data Tables 3-3 and 3-4). Circles outlined in red correspond to female mice. *p < 0.05

**Figure 4.** Bath application of morphine reduces EPSCs at PVT-to-D1-MSN and PVT-to-D2-MSN synapses in Drd1a-tdTomato mice. (A) (Top) Illustration showing injection site of the channelrhodopsin mutant, ChETA, in the PVT and recording site in the NAcSh. (Bottom) DIC and fluorescent images showing that ChETA injection in the PVT evoked ChETA expression in the PVT and nucleus accumbens. Scale bar: 500 μm. (B) Graph showing the amplitude of optically evoked currents at PVT-to-D1-MSN (top) and PVT-to-D2-MSN synapses before and after bath application of morphine (10 μM). Dark circles represent the average and light gray circles show all data points from recorded neurons. Representative traces showing optically evoked paired-pulse EPSCs at both PVT-to-D1-MSN and PVT-to-D2-MSN synapses in the absence (black trace) and presence (gray trace) of bath perfused morphine (10 μM). Scale bars: 50 pA, 10 ms. (C) Summary graph showing the normalized oEPSCs at PVT-to-D1-MSN (9 neurons/4 male mice) and (D) PVT-to-D2-MSN synapses (7 neurons/3 male mice) following bath application of morphine (10 μM). Circles represent individual medium spiny neurons (MSNs). (E) Summary graph showing the percent change at PVT-to-D1-MSN and PVT-to-D2-MSN synapses following bath application of morphine (10 μM). (F) Representative traces showing optically
evoked paired-pulse EPSCs at both PVT-to-D1-MSN and PVT-to-D2-MSN synapses in the absence (black trace) and presence (gray trace) of bath perfused morphine (10 μM). Scale bars: 50 pA, 10 ms. (G) Summary graph showing the paired pulse ratio at PVT-to-D1-MSN synapses before and after morphine bath application (10 μM) (9 neurons from 4 male mice). (H) Summary graph showing the paired pulse ratio at PVT-to-D2-MSN synapses before and after morphine bath application (10 μM) (7 neurons from 3 male mice). (I) Representative traces showing sEPSCs recorded from D1-MSN and D2-MSN in the absence (black trace) and presence (gray trace) of bath perfused morphine (10 μM). Scale bars: 50 pA, 200 ms. (J) Summary graph showing the sEPSC frequency and (K) amplitude on D1-MSNs in the absence and presence of morphine (7 neurons from 4 male mice). (L) Summary graph showing the sEPSC frequency and (M) amplitude on D2-MSNs in the absence and presence of morphine (7 neurons from 3 male mice). **p < 0.01, ***p < 0.001.

**Figure 5.** Inhibition of PVT-to-NAcSh synaptic transmission does not evoke CPP. (A) Experimental timeline and drug regimen for the behavioral procedure ([Extended Data Figure 5-1]). NAcSh cannulated mice were injected with mCherry or hM4di in the PVT. (B) Summary demonstrating viral injection placements in mCherry and hM4di-expressing mice ([Extended Data Figure 5-2]). (Right) A representative image of viral expression in the NAcSh 6 weeks following viral injection of viral constructs in the PVT. Scale bar: 200 μM. (C) Summary graph showing the CPP score in mice conditioned with saline (equal volume) or CNO (3 μM) injected directly into the NAcSh (mCherry-sal: n = 6/6 (male/female); mCherry-CNO: n = 6/6 (male/female); hM4di-sal: n = 6/4 (male/female); hM4di-CNO: n = 5/3 (male/female)) ([Extended Data Tables 5-3 and 5-4]). Circles outlined in red correspond to female mice.
REFERENCES CITED


Bulin SE, Simmons SJ, Richardson DR, Latchney SE, Deutsch HM, Yun S, Eisch AJ (2020) Indices of dentate gyrus neurogenesis are unaffected immediately after or following withdrawal from morphine self-administration compared to saline self-administering control male rats. Behavioural brain research 381:112448.


Gremel CM, Gabriel KI, Cunningham CL (2006) Topiramate does not affect the acquisition or expression of ethanol conditioned place preference in DBA/2J or C57BL/6J mice. Alcoholism, clinical and experimental research 30:783-790.


Figure 2.

A. PVT cannula implant

Days -7 1 2 3 7 8
Hab. Cond. CPP test

B. CPP score

Sal. 50 500 5 μg Morphine

C. CPP score

Sal. Mor. Mor. + CTAP

D. Activity Counts

Chamber Cond. day 1 2 3 4 5
a b a b a b a b a b

E. Activity Counts

Habituation Test
Figure 4.
Figure 5.